Literature DB >> 5657155

Endocavitary treatment of pulmonary mycetomas.

H T Adelson, J A Malcolm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5657155     DOI： 10.1164/arrd.1968.98.1.87

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN： 0003-0805


× No keyword cloud information.
  6 in total

1.  Topical treatment of life threatening haemoptysis from aspergillomas.

Authors:  M Rumbak; G Kohler; C Eastrige; H Winer-Muram; M Gavant
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

2.  Pulmonary monosporosis: an uncommon pulmonary mycotic infection.

Authors:  P C Reddy; C S Christianson; D F Gorelick; H W Larsh
Journal:  Thorax       Date:  1969-11       Impact factor: 9.139

3.  Two unusual organisms, Aspergillus terreus and Metschnikowia pulcherrima, associated with the lung disease of ankylosing spondylitis.

Authors:  W P Kennedy; L J Milne; W Blyth; G K Crompton
Journal:  Thorax       Date:  1972-09       Impact factor: 9.139

Review 4.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

5.  Treatment of symptomatic pulmonary aspergillomas with intracavitary instillation of amphotericin B through an indwelling catheter.

Authors:  M Jackson; C D Flower; J M Shneerson
Journal:  Thorax       Date:  1993-09       Impact factor: 9.139

6.  Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.

Authors:  H J Schmitt; E M Bernard; M Häuser; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.